Druggability & Clinical Context
Druggability
Medium
Score: 0.54
Druggability Analysis
Structural Tractability0.85
Key Metrics
PDB Structures:
25
Known Drugs:
2
Approved:
0
In Clinical Trials:
0
Drug Pipeline (2 compounds)
Therapeutic Areas:ischemic stroke traumatic brain injury multiple sclerosis neuroinflammation blood-brain barrier dysfunction neurodegenerative diseases neurological trauma recovery
Druggability Rationale: MMP9 is highly druggable (0.80 score) as a validated protease target with extensive structural data (25 PDB structures, 1.1 Å resolution), well-characterized zinc-dependent catalytic mechanism, and proven small molecule tractability. However, clinical translation has been challenged by lack of efficacy in Phase 3 oncology trials (Marimastat, Andecaliximab), suggesting that target inhibition alone may be insufficient or that CNS penetration and off-target MMP inhibition complicate therapeutic benefit.
Mechanism: Small molecule zinc-chelating inhibitors or antibody-based inhibition
Drug Pipeline (2 compounds)
Known Drugs:Marimastat (failed_phase_3) — cancer
Andecaliximab (failed_phase_3) — cancer
Structural Data:PDB (25) ✓AlphaFold ✓Cryo-EM —
Binding Pocket Analysis:MMP9 contains a canonical S1' specificity pocket coordinated by a catalytic zinc ion (Zn2+) that is the primary target for chelating inhibitors; the extended substrate binding groove (S1-S4) and hemopexin-like C-terminal domain offer opportunities for selective binder design. High-resolution structures (PDB: 2OVX, 2OVZ) reveal conformational flexibility in the pH-sensitive autoinhibitory pro-domain, relevant for prodomain-selective modulation strategies.
Selectivity & Safety Considerations
MMP9 selectivity is a major challenge due to high sequence homology with MMP2 (72% identity in catalytic domain) and other gelatinases; pan-MMP inhibitors showed poor clinical outcomes, necessitating isoform-selective scaffolds. Off-target inhibition of related MMPs may cause connective tissue toxicity and impair physiological remodeling, a key limitation of first-generation inhibitors like Marimastat.
Clinical Trials (8)
Relevant trials from ClinicalTrials.gov
By Phase
PHASE1: 3 · PHASE2: 2 · PHASE3: 3
PHASE1
NCT07024407
n=10
Heterotopic Ossification (HO)
Interventions: Andecaliximab
Sponsor: Ashibio Inc | Started: 2025-05-14
PHASE2
NCT07500233
n=504
Snakebite
Interventions: 2,3-dimercapto-1-propanesulfonic acid, marimastat, Oral placebo capsules
Sponsor: Liverpool School of Tropical Medicine | Started: 2027-01
PHASE3
NCT00003010
n=334
Breast Cancer
Interventions: marimastat
Sponsor: Eastern Cooperative Oncology Group | Started: 1997-12-02
PHASE3
NCT00002911
Lung Cancer
Interventions: marimastat
Sponsor: ILEX Oncology Services, Incorporated | Started: 1996-12
PHASE3
NCT00003011
n=555
Lung Cancer
Interventions: marimastat, Placebo
Sponsor: NCIC Clinical Trials Group | Started: 1997-01-31
PHASE2
NCT02864381
n=144
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: Andecaliximab, Nivolumab
Sponsor: Gilead Sciences | Started: 2016-09-01
PHASE1
NCT00261391
n=9
Vascular Anomalies
Interventions: Marimastat
Sponsor: Boston Children's Hospital | Started: 2000-10
PHASE1
NCT01803282
n=236
Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer
Interventions: Andecaliximab, Gemcitabine, Nab-paclitaxel
Sponsor: Gilead Sciences | Started: 2013-03-29